Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program.

Autor: White, Randie E.^1,2, Warren, Laura^2,3, Nakhlis, Faina^2,4, Rosenbluth, Jennifer², Bellon, Jennifer^2,3, Block, Caroline², Overmoyer, Beth² Beth_Overmoyer@dfci.harvard.edu

Publikováno v: Breast Journal. Sep2020, Vol. 26 Issue 9, p1688-1694. 7p.

MP22-19 POST-OPERATIVE ANTIBIOTIC PROPHYLAXIS IN RADICAL CYSTECTOMY PATIENTS REDUCES GU INFECTIONS.

Autor: White, Randie E., Linscott, Joshua A., Santos, Erin, Pelletier, Connor, Ryan, Stephen T., Hayn, Matthew T., Howard, Jeffrey E., James, Evelyn, Sammon, Jesse D.

Publikováno v: Journal of Urology; 2024 Supplement 5, Vol. 211, pe351-e351, 1p

Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma

Autor: Gorgun, Gullu Topal, Cowens, Kristen ^*, Paula, Steven ^*, Samur, Mehmet Kemal ^*, Ohguchi, Hiroto ^*, Singh, Ahaana ^*, White, Randie E ^*, Bianchi, Giada, Suzuki, Rikio, Kikuchi, Shohei ^*, Harada, Takeshi ^*, Mimura, Naoya ^*, Tai, Yu-Tzu, Hideshima, Teru, Laubach, Jacob P., Raje, Noopur, Munshi, Nikhil C., Richardson, Paul G., Anderson, Kenneth C.

Publikováno v: In Blood 6 December 2014 124(21):27-27

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Autor: Görgün G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. gullu_gorgun@dfci.harvard.edu kenneth_anderson@dfci.harvard.edu., Samur MK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Department of Biostatistics and Computational Biology, Harvard School of Public Health, Boston, Massachusetts., Cowens KB; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Paula S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Bianchi G; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Anderson JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., White RE; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Singh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Ohguchi H; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Suzuki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Kikuchi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Harada T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Hideshima T; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Tai YT; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Raje N; Massachusetts General Hospital, Boston, Massachusetts., Magrangeas F; Inserm UMR892, CNRS 6299, Université de Nantes, Nantes, France. Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France., Minvielle S; Inserm UMR892, CNRS 6299, Université de Nantes, Nantes, France. Centre Hospitalier Universitaire de Nantes, Unité Mixte de Genomique du Cancer, Nantes, France., Avet-Loiseau H; Unite de Genomique du Myelome, CHU Rangueil, Toulouse, France., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Boston VA Health Care System, Boston, Massachusetts., Dorfman DM; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Anderson KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. gullu_gorgun@dfci.harvard.edu kenneth_anderson@dfci.harvard.edu.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Oct 15; Vol. 21 (20), pp. 4607-18. Date of Electronic Publication: 2015 May 15.